Applied Finance Capital Management LLC Has $12.49 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Applied Finance Capital Management LLC decreased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.3% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 22,219 shares of the biopharmaceutical company’s stock after selling 764 shares during the quarter. Applied Finance Capital Management LLC’s holdings in Regeneron Pharmaceuticals were worth $12,493,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the company. Salomon & Ludwin LLC acquired a new position in Regeneron Pharmaceuticals in the third quarter valued at $27,000. Migdal Insurance & Financial Holdings Ltd. bought a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter worth about $31,000. Traub Capital Management LLC bought a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter worth about $38,000. E Fund Management Hong Kong Co. Ltd. lifted its stake in shares of Regeneron Pharmaceuticals by 87.5% in the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 75 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 35 shares during the period. Finally, Berbice Capital Management LLC boosted its position in shares of Regeneron Pharmaceuticals by 300.0% during the 2nd quarter. Berbice Capital Management LLC now owns 80 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 60 shares in the last quarter. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Stock Performance

REGN opened at $780.28 on Tuesday. The company has a current ratio of 4.13, a quick ratio of 3.39 and a debt-to-equity ratio of 0.09. The company’s fifty day moving average price is $757.89 and its two-hundred day moving average price is $660.34. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $821.11. The company has a market cap of $82.01 billion, a price-to-earnings ratio of 18.77, a PEG ratio of 2.11 and a beta of 0.40.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.74 by $0.70. The firm had revenue of $3.88 billion during the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The business’s revenue was up 2.5% on a year-over-year basis. During the same period last year, the company earned $12.07 earnings per share. On average, analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 5th. Shareholders of record on Friday, February 20th will be issued a dividend of $0.94 per share. The ex-dividend date of this dividend is Friday, February 20th. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. This is an increase from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. Regeneron Pharmaceuticals’s dividend payout ratio is presently 8.47%.

Insider Activity at Regeneron Pharmaceuticals

In other news, Director Bonnie L. Bassler sold 1,500 shares of the firm’s stock in a transaction that occurred on Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total value of $1,200,000.00. Following the transaction, the director owned 1,703 shares in the company, valued at $1,362,400. This trade represents a 46.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 7.02% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on REGN shares. Canaccord Genuity Group lifted their target price on Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the stock a “buy” rating in a report on Thursday, December 4th. Truist Financial reduced their price objective on shares of Regeneron Pharmaceuticals from $820.00 to $818.00 and set a “buy” rating for the company in a research report on Monday, February 2nd. Scotiabank boosted their target price on shares of Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the company a “sector perform” rating in a research report on Monday, November 24th. Bank of America upgraded shares of Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and raised their price target for the stock from $627.00 to $860.00 in a report on Wednesday, January 7th. Finally, Zacks Research raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 8th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $793.81.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.